Revvity RVTY Stock options excluded as their inclusion would be anti-dilutive (in shares)

Stock options excluded as their inclusion would be anti-dilutive (in shares) at other companies

Thermo Fisher ScientificTMO

——

AbbottABT

——

Veeva SystemsVEEV

——

GE HealthCare TechnologiesGEHC

——

Other financials

Income statement

See full

Revenue$711.1M+7.0%

Gross profit$387.7M+3.2%

Operating income$75.9M+5.1%

Net income$40.7M-3.6%

EPS (diluted)$0.36+2.9%

Balance sheet

See full

Cash & equivalents$861.5M-24.3%

Total debt$3.9B+17.8%

Total equity$7.2B-5.9%

Total assets$12.0B-2.9%

Cash flow

See full

Operating cash flow$115.2M-10.1%

CapEx$19.8M+23.7%

Free cash flow$95.5M-14.9%

Valuation

See full

Market cap$11.16B-22.9%

Enterprise value$14.24B-13.7%

P/E46.5×-4.0×

P/S3.8×-1.4×

Profitability

See full

Gross margin48.5%—

Operating margin12.4%-1.1pp

Net margin8.3%-2.1pp

FCF margin17%-1.9pp

Returns & leverage

See full

Return on equity3.2%-0.5pp

Debt / equity0.5×+0.1×

Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.

The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revvity's stock options excluded as their inclusion would be anti-dilutive (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Revvity's stock options excluded as their inclusion would be anti-dilutive (in shares)?: Revvity (RVTY) reported stock options excluded as their inclusion would be anti-dilutive (in shares) of 1.5M in Q1 2026.
How has Revvity's stock options excluded as their inclusion would be anti-dilutive (in shares) changed year-over-year?: Revvity's stock options excluded as their inclusion would be anti-dilutive (in shares) increased by 28.3% year-over-year, from 1.1M to 1.5M.